Basel, Basel, Switzerland
I am passionate about bridging science and solutions, enabling the delivery of safe and effective therapies that transform patient lives. With over a decade of experience in the (bio)pharmaceutical industry, I specialize in supporting drug discovery and development from target assessment through to IND filing. My expertise spans comprehensive immunotoxicology and immunogenicity assessments, leveraging in silico, in vitro, and in vivo models to provide insightful and actionable data for project teams. Having contributed to numerous successful projects, I bring a deep understanding of the complexities involved in drug development across a wide range of therapeutic indications and modalities. My approach ensures tailored strategies that align with project goals while navigating the challenges specific to each drug discovery effort.
• Providing strategic scientific leadership for comprehensive immunosafety risk assessments and immunogenicity mitigation plans, acting as a Subject Matter Expert within multidisciplinary Translational Risk Benefit teams. • Orchestrating the development and implementation of complex in vitro and ex vivo assays by mobilizing and directing matrix-organized resources. • Synthesizing complex safety data to drive regulatory interactions and filing strategies, ensuring alignment across cross-functional expert groups and adherence to global ICH/GLP guidelines.
As for previous position with the following additions: • Leading mechanistic workup of findings in pre-clinical and clinical studies • Contributing to organizational change during and after PS transformation as part of the Portfolio Squad and PS Leadership Network
• Developing immunosafety strategy for innovation and portfolio delivery • Driving the development of new approaches for immunosafety and immunogenicity prediction • Provides expert input to project teams (including due diligences) on safety issues and addresses questions on risk assessment • Delivery of high quality study reports and safety documents
• Exploration of emerging technologies in cancer immune therapy • Support decision making process for new immune therapy technologies • Stage and strategy setting for future immune therapy technologies • Consulting on novel antibody discovery platform
• Antibody discovery preparation • Development of novel antibody discovery platforms (Single Cell Sequencing) • Lead optimization (emphasis on humanization, immunogenicity assessment) In addition, consulting in Immuno-Oncology, planning and executing multi cluster projects, supporting collaborations with external partners.
Developing a non viral gene transfer system for cell based immune therapy. Main focus on T cell receptor gene delivery into mouse and human lymphocytes.
PhD student in the laboratory for Molecular Radiobiology. Investigating ionizing radiation induced signaling pathways in cancer aiming to identify potential targets for the sensitisation to this treatment modality. Focus on post translational protein modification and DNA damage response.
Development of a fully automated cartilage tissue engineering device. Comparative analysis of glucose consumption and cell confluence. Feasibility study for the implementation of a non invasive glucose measuring system. Performing and analyzing test runs on prototypes.